Serial 98253493
Live / Applied — Statement of use — registration review complete (as of 23 Mar 2026)
What this means for you
Not registered yet, but its 03 Nov 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98253493
- Mark type
- Design / logo
- Filed
- 03 Nov 2023
- Published for opposition
- 23 Jul 2024
- Attorney of record
- Andrea Shannon
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use consisting of immunotherapy agents for the treatment and prevention of cancer; vaccine preparations
- Class 042 — Scientific and technological services: Providing medical research and scientific research information in the field of oncology; medical research in the field of oncology; research and development of immunotherapy drugs
Owner
- Diakonos Oncology Corporation, Houston, TX, US
- Diakonos Oncology Corporation, Houston, TX, US
Prosecution history
- 23 Mar 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 23 Mar 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 21 Mar 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 17 Sept 2025 — USE AMENDMENT FILED
- 21 Mar 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 17 Sept 2025 — TEAS STATEMENT OF USE RECEIVED
- 18 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Mar 2025 — SOU EXTENSION 1 GRANTED
- 17 Mar 2025 — SOU EXTENSION 1 FILED
- 17 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 17 Sept 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 23 Jul 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 Jul 2024 — PUBLISHED FOR OPPOSITION
- 03 Jul 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Jun 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER